Biodexa Pharmaceuticals Files 6-K
Ticker: BDRX · Form: 6-K · Filed: Aug 18, 2025 · CIK: 1643918
| Field | Detail |
|---|---|
| Company | Biodexa Pharmaceuticals PLC (BDRX) |
| Form Type | 6-K |
| Filed Date | Aug 18, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, foreign-issuer, pharmaceuticals
Related Tickers: BDRX
TL;DR
Biodexa Pharma (BDRX) filed a 6-K on 8/18/25, confirming 20-F filings.
AI Summary
Biodexa Pharmaceuticals PLC, formerly Midatech Pharma Plc, filed a Form 6-K on August 18, 2025. The company, based in Cardiff, United Kingdom, is a pharmaceutical preparations company. This filing is for the month of August 2025 and indicates the company files annual reports under Form 20-F.
Why It Matters
This filing provides routine updates for investors and regulatory bodies regarding Biodexa Pharmaceuticals PLC's reporting status.
Risk Assessment
Risk Level: low — This is a routine filing that does not contain new material financial or operational information.
Key Players & Entities
- Biodexa Pharmaceuticals PLC (company) — Filer of the 6-K report
- Midatech Pharma Plc (company) — Former name of Biodexa Pharmaceuticals PLC
- August 18, 2025 (date) — Filing date of the 6-K
- Cardiff, United Kingdom (location) — Principal executive office location
- Form 20-F (document) — Annual report filing type
- Form 6-K (document) — Type of filing
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers that are required to file or are permitted to file reports with the SEC, providing information that the issuer makes or is required to make public pursuant to the laws of its home country or that it furnishes or is required to furnish to its security holders.
When was Biodexa Pharmaceuticals PLC previously known as?
Biodexa Pharmaceuticals PLC was formerly known as Midatech Pharma Plc, with a date of name change on June 2, 2015.
Where is Biodexa Pharmaceuticals PLC's principal executive office located?
The principal executive office of Biodexa Pharmaceuticals PLC is located at 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ, United Kingdom.
Does Biodexa Pharmaceuticals PLC file annual reports under Form 20-F?
Yes, the filing indicates by check mark that the registrant files annual reports under cover of Form 20-F.
What is the SIC code for Biodexa Pharmaceuticals PLC?
The Standard Industrial Classification (SIC) code for Biodexa Pharmaceuticals PLC is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 517 words · 2 min read · ~2 pages · Grade level 18.2 · Accepted 2025-08-18 08:31:10
Filing Documents
- f6k_081825.htm (6-K) — 8KB
- exh_991.htm (EX-99.1) — 12KB
- 0001171843-25-005464.txt ( ) — 21KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Biodexa Pharmaceuticals PLC (Registrant) Date: August 18, 2025 /s/ Stephen Stamp Stephen Stamp Chief Executive Officer, Chief Financial Officer